Israel
Nucleix Ltd., founded in 2008 and headquartered in Israel, is making significant strides in the biotechnology sector with its development of cancer diagnostic panels based on epigenetic biomarkers. Positioning itself at the forefront of innovation, Nucleix leverages PCR-based epigenetics to detect cancers at early stages where intervention is crucial, offering a non-invasive solution for patients and healthcare professionals.
Their flagship product, Bladder EpiCheck®, has gained both CE marking in Europe and FDA 510(k) clearance in the U.S., enhancing its credibility and validation in the medical community for bladder cancer recurrence diagnosis. By operating globally from San Diego, California, and Rehovot, Israel, Nucleix has established a robust international presence.
In its most recent funding round on 05 January 2022, the company secured a $22.00M investment from prominent investors including RA Capital Management, OrbiMed, Sands Capital Ventures, and Zohar Zisapel. This infusion of capital underscores investor confidence in Nucleix's potential to transform cancer diagnostics and treatment.
